Exchange: NASDAQ·Updated 04:37 PM EDT
News
all
press releases
Adagio Medical Reports Second Quarter 2026 Results
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. Recent Business Highlights: Announced the successful...
Business Wire
More News
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular session. The company's market cap stands at $1.9 million. Adagio Medical Holdings (NASDAQ:ADGM) shares increased byread more...
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings (NASDAQ:ADGM) stockread more...
Benzinga
Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of the first patient with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation...
Business Wire
Adagio Medical Submits Premarket Approval Application to FDA for vCLAS Ventricular Ablation System for the Treatment of Ventricular Tachycardia
Adagio Medical Holdings, Inc (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the submission of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the...
Business Wire
Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress
Adagio Medical Holdings, Inc (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results...
Business Wire
Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management...
Business Wire
Adagio Medical Announces Positive Pivotal Results for vCLAS Ventricular Ablation System
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported six month results...
Business Wire
Adagio Medicals ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that its...
Business Wire
Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS Ventricular Ablation System
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to...
Business Wire

Advertisement|Remove ads.